title: Enhancing the potency of therapeutic monoclonal antibodies via Fc optimization.
authors.affiliation: MacroGenics, Inc., 1500 East Gude Drive, Rockville, MD 20850, USA. stavenhagenj@macrogenics.com
authors.forename: Jeffrey B
authors.initials: JB
authors.lastname: Stavenhagen
authors.forename: Sergey
authors.initials: S
authors.lastname: Gorlatov
authors.forename: Nadine
authors.initials: N
authors.lastname: Tuaillon
authors.forename: Christopher T
authors.initials: CT
authors.lastname: Rankin
authors.forename: Hua
authors.initials: H
authors.lastname: Li
authors.forename: Stephen
authors.initials: S
authors.lastname: Burke
authors.forename: Ling
authors.initials: L
authors.lastname: Huang
authors.forename: Syd
authors.initials: S
authors.lastname: Johnson
authors.forename: Scott
authors.initials: S
authors.lastname: Koenig
authors.forename: Ezio
authors.initials: E
authors.lastname: Bonvini
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity / Q000235:genetics; D007141:Immunoglobulin Fc Fragments / Q000235:genetics / Q000502:physiology*; D007074:Immunoglobulin G / Q000378:metabolism; D016393:Lymphoma, B-Cell / Q000188:drug therapy; D051379:Mice; D009374:Neoplasms, Experimental / Q000188:drug therapy; D015202:Protein Engineering; D011961:Receptors, Fc / Q000502:physiology*; D017452:Receptors, IgG / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000378:metabolism; D012441:Saccharomyces cerevisiae / Q000378:metabolism
chemical_list: D000911:Antibodies, Monoclonal; C080571:Fc gamma receptor IIB; D007141:Immunoglobulin Fc Fragments; D007074:Immunoglobulin G; D011961:Receptors, Fc; D017452:Receptors, IgG; D011993:Recombinant Fusion Proteins